SCS Capital Management LLC
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1303159
BOSTON, MA
Position in REGN
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$293,687
-$70,226 QoQ
Shares Held
471
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#951
of 1,322 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SCS Capital Management LLC holds $68,891,949 across 16 Biotechnology names. REGN ranks #10 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
115,549 | $34,783,715 | |
| 2 | AGIO |
Agios Pharmaceuticals, Inc.
|
612,850 | $22,742,863 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
197,998 | $5,092,508 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
53,430 | $1,586,336 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
9,375 | $913,875 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
3,867 | $724,211 | |
| 7 | ANNX |
Annexon, Inc.
|
99,000 | $565,290 | |
| 8 | FHTX |
Foghorn Therapeutics Inc.
|
106,980 | $522,062 |
All Filings in REGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $293,687 | 471 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $363,913 | 471 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $362,778 | 470 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $265,391 | 472 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||